ClinicalTrials.gov record
Terminated Phase 3 Interventional

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

ClinicalTrials.gov ID: NCT03702920

Public ClinicalTrials.gov record NCT03702920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality

Study identification

NCT ID
NCT03702920
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Grifols Therapeutics LLC
Industry
Enrollment
275 participants

Conditions and interventions

Interventions

  • SMT + PE-A 5% Biological
  • Standard Medical Treatment Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 20, 2019
Primary completion
Apr 13, 2025
Completion
Apr 13, 2025
Last update posted
Dec 15, 2025

2019 – 2025

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
University of Alabama at Birmingham (UAB) Hospital Birmingham Alabama 35294
Mayo Clinic Phoenix Phoenix Arizona 85054
Southern California Research Center Coronado California 92118
Cedars-Sinai Medical Center Los Angeles California 90048
Emory University Atlanta Georgia 30322
University of Kansas Kansas City Kansas 66045
Rutgers-New Jersey Medical School Newark New Jersey 07101
University of New Mexico Albuquerque New Mexico 87131
Mayo Clinic Rochester Rochester New York 55905
Ohio State University Wexner Medical Center Columbus Ohio 43210
University of Pennsylvania Philadelphia Pennsylvania 19104
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
McGuire VA Medical Center Richmond Virginia 23249
University of Washington Medical Center Seattle Washington 98195
Aurora Health Care, Inc. Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03702920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 15, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03702920 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →